JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on CTNM stock, giving a Buy rating on June 18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Debanjana Chatterjee’s rating is based on several factors that indicate a positive outlook for Contineum Therapeutics, Inc. Class A. The company is progressing well with its Phase 1b PET trial of PIPE-791, which is crucial for determining the appropriate dosage for the upcoming Phase 2 trials. Despite a minor delay in the expected timeline for the topline data release, the enrollment for the healthy volunteer and PrMS cohorts is complete, and recruitment is ongoing for the IPF cohort.
Chatterjee views the delay as insignificant and believes it will not affect the planned start of the Phase 2 trials in the second half of 2025. The focus remains on the brain imaging data, which is anticipated to provide more valuable insights compared to the lung data. With a strong cash position and strategic progress in trial enrollments, Chatterjee maintains a Buy rating, reflecting confidence in the company’s ability to achieve its clinical milestones.
According to TipRanks, Chatterjee is a 4-star analyst with an average return of 13.8% and a 47.62% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Tvardi Therapeutics, KalVista Pharmaceuticals, and Intellia Therapeutics.